CURX

+ Watchlist + Portfolio

Curanex Pharmaceuticals Inc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.41
52-Week Range: $3.58 – $183.59
Market Cap: $8.26M
P/E (TTM): —
EPS (TTM): -7.19
Dividend Yield: —

Advanced Metrics

Price/Book: 405.38
PEG Ratio: —
Return on Equity: -411.08%
Return on Assets: -225.06%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 45.95
Debt/Equity: 0.06
Total Debt: $276.36K
Free Cash Flow: $-7.72M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $162.63M

CURX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$26.00K	$0.00	$0.00	$0.00
Cost of Revenue	$21.57K	$0.00	—	—
Gross Profit	$4.43K	$0.00	—	—
Research & Development	—	—	$0.00	$2.99M
Selling, General & Admin	$24.66K	$19.30K	$290.39K	$1.25M
Operating Expenses	$24.66K	$19.30K	$290.39K	$4.24M
Operating Income	-$20.23K	-$19.30K	-$290.39K	-$4.24M
EBITDA	$925.00	-$17.48K	-$361.51K	-$4.14M
Pretax Income	-$20.23K	-$19.20K	-$361.51K	-$4.23M
Net Income	-$20.23K	-$19.20K	-$361.51K	-$4.23M
Diluted EPS	-0.02	-0.00	-0.01	-0.17
Diluted Shares	42.00M	42.00M	42.00M	25.50M

CURX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.43K	$74.37K	$148.89K	$4.97M
Receivables	$3.00K	$0.00	—	—
Inventory	$2.99K	$0.00	—	—
Current Assets	$10.23K	$74.37K	$517.93K	$11.23M
Total Assets	$10.23K	$74.37K	$517.93K	$11.58M
Current Liabilities	$0.00	$14.28K	$14.57K	$137.03K
Total Debt	—	—	$0.00	$346.70K
Total Liabilities	$0.00	$14.28K	$14.57K	$361.04K
Retained Earnings	-$241.75K	-$260.94K	-$622.45K	-$4.85M
Shareholders' Equity	$10.23K	$60.09K	$503.36K	$11.22M
Working Capital	$10.23K	$60.09K	$503.36K	$11.09M

CURX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$3.34K	-$120.00	-$555.58K	-$10.48M
Free Cash Flow	$3.34K	-$120.00	-$555.58K	-$10.48M
Depreciation & Amortisation	$21.16K	$1.81K	$0.00	$79.40K
Financing Cash Flow	-$3.00K	$72.06K	$630.10K	$15.31M
Net Change in Cash	$336.00	$71.94K	$74.53K	$4.82M

CURX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$0.00	—	$677.47K	$2.31M	$2.26M
Selling, General & Admin	$137.45K	$57.66K	$273.85K	$786.34K	$927.20K
Operating Expenses	$137.45K	$57.66K	$951.33K	$3.09M	$3.18M
Operating Income	-$137.45K	-$57.66K	-$951.33K	-$3.09M	-$3.18M
EBITDA	-$121.59K	-$42.23K	-$934.53K	-$3.04M	-$3.12M
Pretax Income	-$137.58K	-$60.35K	-$954.06K	-$3.07M	-$3.15M
Net Income	-$137.58K	-$60.35K	-$954.06K	-$3.07M	-$3.15M
Diluted EPS	-0.00	-0.00	-0.04	—	-0.11
Diluted Shares	27.75M	27.75M	25.60M	—	28.34M

CURX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$198.94K	$108.86K	$5.83M	$4.97M	$4.02M
Current Assets	$696.07K	$711.34K	$14.42M	$11.23M	$8.09M
Total Assets	$786.94K	$787.17K	$14.48M	$11.58M	$8.41M
Current Liabilities	$192.60K	$75.93K	$185.96K	$137.03K	$128.73K
Long-Term Debt	$200.00K	$400.00K	—	—	—
Total Debt	$291.18K	$476.45K	$61.15K	$346.70K	$311.00K
Total Liabilities	$421.16K	$481.74K	$185.96K	$361.04K	$332.64K
Retained Earnings	-$760.03K	-$820.38K	-$1.77M	-$4.85M	-$8.00M
Shareholders' Equity	$365.78K	$305.43K	$14.29M	$11.22M	$8.08M
Working Capital	$503.47K	$635.41K	$14.23M	$11.09M	$7.96M
Net Debt	$1.06K	$291.14K	—	—	—

CURX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$149.95K	-$290.08K	-$9.19M	-$857.40K	-$954.56K
Free Cash Flow	-$149.95K	-$290.08K	-$9.19M	-$857.40K	-$954.56K
Depreciation & Amortisation	$14.63K	$15.03K	$15.44K	$34.29K	$35.04K
Stock-Based Compensation	$0.00	—	—	—	$9.79K
Financing Cash Flow	$200.00K	$200.00K	$14.91M	$0.00	$0.00
Net Change in Cash	$50.05K	-$90.08K	$5.72M	-$857.40K	-$954.56K

Market Snapshot

About

Curanex Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. The company's research and development efforts target treatments for various diseases and medical conditions. Curanex Pharmaceuticals pursues both proprietary drug candidates and licensing opportunities to build its product pipeline. The company operates in the competitive pharmaceutical development sector, where successful candidates must navigate lengthy clinical trials and regulatory approval processes.